EVQLV Media

The Depth, Vision and Progress of EVQLV

The Depth, Vision and Progress of EVQLV

Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies’ “Alumni in Action.” The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term plans of our company

read more
EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies

EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

read more
What we do and how we do it

What we do and how we do it

EVQLV uses artificial intelligence (AI) to discover and optimize novel biologics. Our algorithm uses an evolutionary approach with applied external pressures to generate candidates. There’s a lot more to it, but we thought you might enjoy a taste of our “secret sauce.”

read more
Combatting COVID-19: Innovative Efforts

Combatting COVID-19: Innovative Efforts

We’re not sharing this information to scare, but instead to inform on the challenges the healthcare industry is facing. With that in mind, below we report on 21 innovative efforts from leading and emerging players in the biotech industry to combat the COVID-19 pandemic.

read more

Pin It on Pinterest